Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
4.400
-0.200 (-4.35%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Orchestra BioMed Holdings Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Orchestra BioMed Holdings stock have an average target of 15.4, with a low estimate of 12 and a high estimate of 20. The average target predicts an increase of 250.00% from the current stock price of 4.40.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Orchestra BioMed Holdings stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +172.73% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +218.18% | Mar 10, 2025 |
| Barclays | Barclays | Buy Initiates $16 | Buy | Initiates | $16 | +263.64% | Jan 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +218.18% | Nov 15, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +354.55% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
3.38M
from 2.76M
Increased by 22.61%
Revenue Next Year
3.95M
from 3.38M
Increased by 16.64%
EPS This Year
-1.69
from -1.48
EPS Next Year
-1.97
from -1.69
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.2M | 5.3M | 5.3M | |||
| Avg | 3.4M | 3.9M | 4.0M | |||
| Low | 2.7M | 2.7M | 2.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 52.2% | 55.1% | 33.0% | |||
| Avg | 22.6% | 16.6% | 0.2% | |||
| Low | -1.7% | -21.4% | -30.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.73 | -1.81 | -1.67 | |||
| Avg | -1.69 | -1.97 | -1.78 | |||
| Low | -1.64 | -2.05 | -1.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.